BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sarah Aebersold Sells 5,632 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Sarah Aebersold sold 5,632 shares of the firm’s stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $24.96, for a total transaction of $140,574.72. Following the transaction, the insider now directly owns 45,860 shares of the company’s stock, valued at $1,144,665.60. The trade was a 10.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Sarah Aebersold also recently made the following trade(s):

• On Monday, March 17th, Sarah Aebersold sold 2,695 shares of BioLife Solutions stock. The stock was sold at an average price of $25.44, for a total transaction of $68,560.80.
• On Tuesday, March 11th, Sarah Aebersold sold 1,091 shares of BioLife Solutions stock. The stock was sold at an average price of $25.00, for a total transaction of $27,275.00.
• On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total transaction of $6,484.80.

BioLife Solutions Price Performance

BLFS traded down $0.59 during midday trading on Tuesday, hitting $25.33. The company had a trading volume of 376,894 shares, compared to its average volume of 348,703. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The company has a market capitalization of $1.19 billion, a PE ratio of -23.90 and a beta of 2.04. BioLife Solutions, Inc. has a twelve month low of $14.84 and a twelve month high of $29.55. The firm’s 50-day simple moving average is $26.56 and its 200-day simple moving average is $25.49.

BioLife Solutions (NASDAQ:BLFS) last posted its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.32. The firm had revenue of $22.71 million during the quarter, compared to analysts’ expectations of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same quarter last year, the company posted ($0.21) EPS. Equities research analysts predict that BioLife Solutions, Inc. will post -0.3 EPS for the current fiscal year.

Institutional Investors Weigh In On BioLife Solutions

Institutional investors have recently modified their holdings of the business. Steward Partners Investment Advisory LLC acquired a new stake in shares of BioLife Solutions during the 4th quarter worth approximately $26,000. Mark Sheptoff Financial Planning LLC acquired a new stake in shares of BioLife Solutions during the 3rd quarter worth approximately $28,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of BioLife Solutions during the 4th quarter worth approximately $31,000. Quest Partners LLC acquired a new stake in shares of BioLife Solutions during the 3rd quarter worth approximately $57,000. Finally, 1620 Investment Advisors Inc. grew its position in shares of BioLife Solutions by 41.7% during the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock worth $60,000 after buying an additional 675 shares during the period. Institutional investors and hedge funds own 93.24% of the company’s stock.

Wall Street Analysts Forecast Growth

BLFS has been the subject of a number of recent analyst reports. KeyCorp increased their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Benchmark reiterated a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a research report on Thursday, December 19th. Northland Securities increased their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 8th. Finally, HC Wainwright increased their target price on shares of BioLife Solutions from $27.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to MarketBeat.com, BioLife Solutions currently has an average rating of “Moderate Buy” and an average price target of $29.86.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.